Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs

被引：0

作者：

Hermann M. ^{[1
]}

机构：

[1] Department of Cardiology, University Hospital Zürich, CH-8091 Zürich

来源：

Current Rheumatology Reports | 2009年 / 11卷 / 1期

关键词：

Ibuprofen; Paracetamol; Celecoxib; Naproxen; Rofecoxib;

D O I：

10.1007/s11926-009-0005-5

中图分类号：

学科分类号：

摘要：

Since the introduction of selective cyclooxygenase-2 inhibitors (coxibs), there has been an ongoing discussion about the cardiovascular (CV) safety of coxibs and the traditional nonsteroidal anti-inflammatory drugs (NSAIDs). Available data about the CV safety of NSAIDs come mostly from meta-analyses and a few clinical trials. Current evidence suggests that NSAIDs may increase the risk of CV events. Naproxen might be associated with lower risk, but available data are not conclusive. Recent recommendations on the treatment of patients with NSAIDs favor the use of naproxen in patients with increased CV risk. Therefore, this review focuses on data about naproxen and examines CV risk with ibuprofen and non-naproxen NSAIDs. In addition, data about CV safety of paracetamol (acetaminophen) are presented. © Springer Science+Business Media, LLC 2009.

引用

页码：31 / 35

页数：4

共 34 条

[1]

Graham D.J., Campen D., Hui R., Et al., Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: Nested case-control study, Lancet, 365, pp. 475-481, (2005)

[2]

Chan A.T., Manson J.E., Albert C.M., Et al., Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events, Circulation, 113, pp. 1578-1587, (2006)

[3]

Forman J.P., Stampfer M.J., Curhan G.C., Non-narcotic analgesic dose and risk of incident hypertension in US women, Hypertension, 46, pp. 500-507, (2005)

[4]

Warner T.D., Mitchell J.A., COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs, Lancet, 371, pp. 270-273, (2008)

[5]

Kearney P.M., Baigent C., Godwin J., Et al., Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials, BMJ, 332, pp. 1302-1308, (2006)

[6]

McGettigan P., Henry D., Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2, JAMA, 296, pp. 1633-1644, (2006)

[7]

Andersohn F., Schade R., Suissa S., Garbe E., Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: A nested case-control study, Stroke, 37, pp. 1725-1730, (2006)

[8]

Singh G., Wu O., Langhorne P., Madhok R., Risk of acute myocardial infarction with nonselective non-steroidal antiinflammatory drugs: A meta-analysis, Arthritis Res Ther, 8, (2006)

[9]

Salpeter S.R., Gregor P., Ormiston T.M., Et al., Meta-analysis: Cardiovascular events associated with nonsteroidal antiinflammatory drugs, Am J Med, 119, pp. 552-559, (2006)

[10]

Bombardier C., Laine L., Reicin A., Et al., Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med, 343, pp. 1520-1528, (2000)

← 1 2 3 4 →